Not particularly surprising to see a $9m 2HFY17 revenue figure (and ~$3m 2HFY17 EBITDA loss) given they've seemingly completely ceased production of the main business line. Doubt they'll get much out of the diversified product suite in FY18, either, given most have either just launched or are about to launch.
The waiting game continues. With a ~$30m EV, it remains a cheap option on both an oil price recovery and any success from their new products, and they ain't going broke given the net cash position.
Potential for 'strategic acquisitions' unnerves me, though. I'm sure it's a good time to buy assets in MCE's industry given conditions are horrendous (i.e. assets are cheap), but if they fund such an acquisition by raising equity when MCE's own stock is beaten down it kind of defeats the whole purpose.
- Forums
- ASX - By Stock
- MCE
- Ann: Company update and diversification strategy
Ann: Company update and diversification strategy, page-2
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MCE (ASX) to my watchlist
(20min delay)
|
|||||
Last
27.5¢ |
Change
0.045(19.6%) |
Mkt cap ! $72.45M |
Open | High | Low | Value | Volume |
26.0¢ | 29.0¢ | 26.0¢ | $57.59K | 205.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 7703 | 27.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.0¢ | 36500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14995 | 0.290 |
1 | 8500 | 0.285 |
1 | 6500 | 0.280 |
1 | 15000 | 0.270 |
1 | 10000 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 3031 | 1 |
0.340 | 3649 | 1 |
0.345 | 12762 | 1 |
0.350 | 98847 | 3 |
0.360 | 30000 | 1 |
Last trade - 15.48pm 25/11/2024 (20 minute delay) ? |
Featured News
MCE (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online